1
|
Al-Yasiri AY, Khoobchandani M, Cutler CS, Watkinson L, Carmack T, Smith CJ, Kuchuk M, Loyalka SK, Lugão AB, Katti KV. Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy. Dalton Trans 2017; 46:14561-14571. [DOI: 10.1039/c7dt00383h] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We report here production of MGF-198AuNPs and its application for prostate tumor therapy.
Collapse
Affiliation(s)
- A. Y. Al-Yasiri
- Nuclear Science and Engineering Institute (NSEI)
- University of Missouri
- Columbia
- USA
| | - M. Khoobchandani
- Department of Radiology
- Institute of Green Nanotechnology
- University of Missouri
- One Hospital Drive
- Columbia
| | - C. S. Cutler
- Nuclear Science and Engineering Institute (NSEI)
- University of Missouri Research Reactor (MURR)
- University of Missouri
- Columbia
- USA
| | - L. Watkinson
- Harry S. Truman Memorial Veterans Hospital
- University of Missouri
- One Hospital Drive
- Columbia
- USA
| | - T. Carmack
- Harry S. Truman Memorial Veterans Hospital
- University of Missouri
- One Hospital Drive
- Columbia
- USA
| | - C. J. Smith
- Department of Radiology
- Harry S. Truman Memorial Veterans Hospital
- University of Missouri
- One Hospital Drive
- Columbia
| | - M. Kuchuk
- University of Missouri Research Reactor (MURR)
- University of Missouri
- One Hospital Drive
- Columbia
- USA
| | - S. K. Loyalka
- Nuclear Science and Engineering Institute (NSEI)
- University of Missouri
- Columbia
- USA
| | - A. B. Lugão
- Nuclear and Energy Research Institute – IPEN/CNEN/Sao Paulo
- Brazil
| | - K. V. Katti
- Nuclear Science and Engineering Institute (NSEI)
- Department of Radiology
- Institute of Green Nanotechnology
- University of Missouri Research Reactor (MURR)
- Harry S. Truman Memorial Veterans Hospital
| |
Collapse
|
2
|
Wallace T, Torre T, Grob M, Yu J, Avital I, Brücher BLDM, Stojadinovic A, Man Y. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer 2014; 5:3-24. [PMID: 24396494 PMCID: PMC3881217 DOI: 10.7150/jca.7709] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2013] [Accepted: 11/01/2013] [Indexed: 01/23/2023] Open
Abstract
Prostate cancer is the most commonly diagnosed non-cutaneous neoplasm in men in the United States and the second leading cause of cancer mortality. One in 7 men will be diagnosed with prostate cancer during their lifetime. As a result, monitoring treatment response is of vital importance. The cornerstone of current approaches in monitoring treatment response remains the prostate-specific antigen (PSA). However, with the limitations of PSA come challenges in our ability to monitor treatment success. Defining PSA response is different depending on the individual treatment rendered potentially making it difficult for those not trained in urologic oncology to understand. Furthermore, standard treatment response criteria do not apply to prostate cancer further complicating the issue of treatment response. Historically, prostate cancer has been difficult to image and no single modality has been consistently relied upon to measure treatment response. However, with newer imaging modalities and advances in our understanding and utilization of specific biomarkers, the future for monitoring treatment response in prostate cancer looks bright.
Collapse
Affiliation(s)
- T.J. Wallace
- 1. Bon Secours Cancer Institute, Bon Secours Health Care System, Richmond VA, USA
- 2. Division of Radiation Oncology, Bon Secours Health Care System, Richmond VA, USA
- 3. Virginia Urology, Richmond VA, USA
| | - T. Torre
- 1. Bon Secours Cancer Institute, Bon Secours Health Care System, Richmond VA, USA
- 2. Division of Radiation Oncology, Bon Secours Health Care System, Richmond VA, USA
- 3. Virginia Urology, Richmond VA, USA
| | - M. Grob
- 4. Department of Urology, Virginia Commonwealth University Health System, Richmond VA, USA
| | - J. Yu
- 5. Department of Radiology, Virginia Commonwealth University Health System, Richmond VA, USA
| | - I. Avital
- 1. Bon Secours Cancer Institute, Bon Secours Health Care System, Richmond VA, USA
- 6. Division of Surgical Oncology, Bon Secours Health Care System, Richmond VA, USA
| | - BLDM Brücher
- 1. Bon Secours Cancer Institute, Bon Secours Health Care System, Richmond VA, USA
- 6. Division of Surgical Oncology, Bon Secours Health Care System, Richmond VA, USA
- 7. INCORE, International Consortium of Research Excellence of the Theodor-Billroth-Adademy
| | - A. Stojadinovic
- 1. Bon Secours Cancer Institute, Bon Secours Health Care System, Richmond VA, USA
- 6. Division of Surgical Oncology, Bon Secours Health Care System, Richmond VA, USA
- 7. INCORE, International Consortium of Research Excellence of the Theodor-Billroth-Adademy
| | - Y.G. Man
- 1. Bon Secours Cancer Institute, Bon Secours Health Care System, Richmond VA, USA
- 6. Division of Surgical Oncology, Bon Secours Health Care System, Richmond VA, USA
- 8. South Hospital of Nanjing, Nanjing, China
| |
Collapse
|
3
|
Haworth A, Williams S, Reynolds H, Waterhouse D, Duchesne GM, Bucci J, Joseph D, Bydder S, Ebert M. Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning. Brachytherapy 2013; 12:628-36. [DOI: 10.1016/j.brachy.2013.04.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2013] [Revised: 04/10/2013] [Accepted: 04/15/2013] [Indexed: 10/26/2022]
|
4
|
Wenske S, Quarrier S, Katz AE. Salvage Cryosurgery of the Prostate for Failure After Primary Radiotherapy or Cryosurgery: Long-term Clinical, Functional, and Oncologic Outcomes in a Large Cohort at a Tertiary Referral Centre. Eur Urol 2013; 64:1-7. [PMID: 22840351 DOI: 10.1016/j.eururo.2012.07.008] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2012] [Accepted: 07/09/2012] [Indexed: 10/28/2022]
|
5
|
Pathological Characteristics of Prostate Cancer Recurrence After Radiation Therapy: Implications for Focal Salvage Therapy. J Urol 2012; 188:98-102. [DOI: 10.1016/j.juro.2012.02.2571] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2011] [Indexed: 11/16/2022]
|
6
|
Ahmed HU, Cathcart P, McCartan N, Kirkham A, Allen C, Freeman A, Emberton M. Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. Cancer 2012; 118:4148-55. [PMID: 22907704 DOI: 10.1002/cncr.27394] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2011] [Revised: 11/09/2011] [Accepted: 11/14/2011] [Indexed: 11/10/2022]
Abstract
BACKGROUND The objective of this study was to evaluate the safety, feasibility, side-effect profile, and proof of concept for focal salvage therapy using high-intensity focused ultrasound (HIFU). METHODS A registry-based analysis was conducted between 2004 and 2009 of 430 patients who underwent HIFU. Thirty-nine patients received focal salvage therapy for localized recurrence after external beam radiotherapy. Multiparametric magnetic resonance imaging studies combined with transperineal template prostate mapping biopsies or transrectal biopsies were used to localize disease. Validated questionnaires were used to assess functional outcomes. Biochemical failure was defined by using both Phoenix criteria (prostate-specific antigen [PSA] nadir plus 2 ng/mL) and Stuttgart criteria (PSA nadir plus 1.2 ng/mL). RESULTS The mean pre-HIFU PSA level was 4.6 ng/mL. The median follow-up was 17 months (interquartile range, 10-29 months). International Index of Erectile Function-5 scores decreased from a median ± standard deviation (SD) of 18 ± 16 to 13 ± 21 at 6 months, demonstrating worsening function. Scores on the University of California Los Angeles-Expanded Prostate Cancer Index Composite Urinary domain indicate that pad-free, leak-free continence status was 64%, and the pad-free rate was 87.2% at last follow-up. One rectourethral fistula occurred and spontaneously resolved with urinary and bowel diversion. The actuarial progression-free survival rate (including PSA nonresponders) was 69% at 1 year and 49% at 2 years according to Phoenix criteria. Excluding PSA nonresponders, these rates were 74% and 58%, respectively (Phoenix criteria). CONCLUSIONS The results from this study indicated that focal salvage therapy is a potential strategy for localized recurrence after radiotherapy that may reduce the harms resulting from whole-gland salvage therapies.
Collapse
Affiliation(s)
- Hashim Uddin Ahmed
- Division of Surgery and Interventional Science, University College London, London, United Kingdom.
| | | | | | | | | | | | | |
Collapse
|